Want to see IN:BAJAJHCARE full AI Analyst Report?
BAJAJHCARE Stock Chart & Stats
₹418.50
-₹31.80(-5.51%)
At close: 4:00 PM EST
₹418.50
-₹31.80(-5.51%)
Day’s Range― - ―
52-Week Range₹272.45 - ₹516.20
Previous CloseN/A
Volume215.90K
Average Volume (3M)4.99K
Market Cap
₹11.33B
Enterprise Value₹17.66K
Total Cash (Recent Filing)₹379.87M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)62.4
Beta1.33
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.3%
Share Statistics
EPS (TTM)5.39
Shares Outstanding33,662,663
10 Day Avg. Volume2,706
30 Day Avg. Volume4,987
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)1.72
Price to Sales (P/S)1.50
P/FCF Ratio-149.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA FY2026 revenue rebound of +6.4% signals demand stabilization and improving top-line momentum across API and formulation segments. Durable recovery supports higher capacity utilization, steadier customer contracts and potential scale benefits that can lift medium-term cash flows if maintained.
Improved LeverageA materially lower debt-to-equity (~0.47) versus prior years reduces refinancing and liquidity risk, increasing financial flexibility. This steadier capital structure gives management more room to fund capex, comply with regulatory investments and pursue steady exports without immediate balance-sheet strain.
Gross & Operating Margin StrengthImproved gross margin (~33%) and mid-teens EBITDA margins indicate durable unit economics from product mix or cost control. Sustained operating profitability creates capacity to invest in quality/compliance, supports customer retention in generics/APIs and provides a cushion against raw-material cycles.
Bears Say
Net Margin CompressionA sharp fall in net margin to ~2.6% signals higher below-the-line costs or one-offs that erode shareholder returns. Persistently low net profitability reduces retained earnings accumulation, weakens ROE recovery prospects and reduces the buffer versus cyclical downturns or regulatory expense shocks.
Negative Free Cash FlowOngoing negative free cash flow despite positive operating cash flow shows working-capital strain or heavy reinvestment needs. Persistent FCF deficits force reliance on external funding, constrain deleveraging or dividend capacity and increase vulnerability to tightening credit conditions over the medium term.
Volatile Returns And Sizable DebtHistoric ROE volatility and a past negative ROE highlight inconsistent earnings conversion. Coupled with a meaningful absolute debt load (~2.49B), this amplifies refinancing and interest-cost risk if margins slip, making sustainable recovery dependent on consistent profit and cash-flow improvement.
Bajaj Healthcare Ltd News
BAJAJHCARE FAQ
What was Bajaj Healthcare Ltd’s price range in the past 12 months?
Bajaj Healthcare Ltd lowest stock price was ₹272.45 and its highest was ₹516.20 in the past 12 months.
What is Bajaj Healthcare Ltd’s market cap?
Bajaj Healthcare Ltd’s market cap is ₹11.33B.
When is Bajaj Healthcare Ltd’s upcoming earnings report date?
Bajaj Healthcare Ltd’s upcoming earnings report date is Nov 06, 2026 which is in 89 days.
How were Bajaj Healthcare Ltd’s earnings last quarter?
Bajaj Healthcare Ltd released its earnings results on Jul 20, 2026. The company reported ₹4.069 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Bajaj Healthcare Ltd overvalued?
According to Wall Street analysts Bajaj Healthcare Ltd’s price is currently Overvalued.
Does Bajaj Healthcare Ltd pay dividends?
Bajaj Healthcare Ltd pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.3%. See more information on Bajaj Healthcare Ltd dividends here
What is Bajaj Healthcare Ltd’s EPS estimate?
Bajaj Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bajaj Healthcare Ltd have?
Bajaj Healthcare Ltd has 33,662,663 shares outstanding.
What happened to Bajaj Healthcare Ltd’s price movement after its last earnings report?
Bajaj Healthcare Ltd reported an EPS of ₹4.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.901%.
Which hedge fund is a major shareholder of Bajaj Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:BAJAJHCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bajaj Healthcare Ltd
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 amino 1 adamantanol, N boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
Technical Analysis
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Themis Medicare Limited
―
Wanbury Limited
―








